A Risk-Based Auditing Process for Pharmaceutical Manufacturers

References

1. 1.↵
   International Conference on Harmonization. ICH Q9. Guideline on Quality Risk Management, November 2005.
2. 2.↵
   1. Rönninger S.,
   2. Schmitt S.,
   3. Rangavajhula V.,
   4. Lyda J.,
   5. Hough E.

   Considerations on auditing and GxP requirements along the product life cycle. PDA J. Pharm. Sci. Technol. 2012, 66(5), 396–402.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   PDA Technical Report No. 54 (TR 54) Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations, 2012.
4. 4.↵
   1. Rönninger S.,
   2. Holmes M.

   A risk-based approach for scheduling audits. PDA J. Pharm. Sci. Technol. 2009, 63(6), 575–588.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   PIC/S. A Recommended Model for Risk Based Inspection Planning in the GMP Environment. PI 037-1, January 1, 2012.
6. 6.↵
   Health Canada. Health Products and Food Branch, Risk Classification of Post-Market Reporting Compliance Observations, Guide-0063, November 21, 2005.
7. 7.↵
   European Medicines Agency. Compilation of Community Procedures on Inspections and Exchange of Information, EMA/INS/GMP/321252/2012/Rev. 15, July 16, 2012.
8. 8.↵
   1. Rönninger S.,
   2. Berberich J.,
   3. Fischer G.,
   4. Persson I.,
   5. Wandt C.,
   6. Wall L.

   How can we balance value, effort and risk in foreign GMP inspections? A future perspective. GMP Review, 2012, 10, 14–18.

   OpenUrl